Recent studies have shown that PPARα agonists, such as FENO, have the potential to decrease TNF-α and TGF-β expression in animal-based experiments, thus ameliorating the damage caused by NASH. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatohepatitis.